PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more
PureTech Health PLC - Asset Resilience Ratio
PureTech Health PLC (PRTC) has an Asset Resilience Ratio of 10.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how PureTech Health PLC's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PureTech Health PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $59.30 Million | 10.72% |
| Total Liquid Assets | $59.30 Million | 10.72% |
Asset Resilience Insights
- Moderate Liquidity: PureTech Health PLC has 10.72% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
PureTech Health PLC Industry Peers by Asset Resilience Ratio
Compare PureTech Health PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for PureTech Health PLC (2012–2024)
The table below shows the annual Asset Resilience Ratio data for PureTech Health PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.38% | $86.67 Million | $602.63 Million | -5.23pp |
| 2023-12-31 | 19.61% | $136.06 Million | $693.97 Million | -8.89pp |
| 2022-12-31 | 28.50% | $200.23 Million | $702.65 Million | +28.63pp |
| 2021-12-31 | -0.14% | $-1.28 Million | $946.01 Million | +0.04pp |
| 2020-12-31 | -0.17% | $-1.70 Million | $989.99 Million | -3.37pp |
| 2019-12-31 | 3.20% | $30.09 Million | $941.18 Million | -27.10pp |
| 2018-12-31 | 30.29% | $133.83 Million | $441.76 Million | -4.14pp |
| 2017-12-31 | 34.43% | $117.03 Million | $339.85 Million | -39.01pp |
| 2016-12-31 | 73.44% | $219.41 Million | $298.75 Million | +18.42pp |
| 2015-12-31 | 55.02% | $179.78 Million | $326.75 Million | +54.51pp |
| 2014-12-31 | 0.51% | $1.17 Million | $228.03 Million | -10.41pp |
| 2013-12-31 | 10.92% | $1.83 Million | $16.77 Million | +4.79pp |
| 2012-12-31 | 6.13% | $1.18 Million | $19.18 Million | -- |